Importation from Canada dropping
According to Health Canada, there has been a substantial and steady decline in cross-border drug sales since the beginning of 2006 - a trend that could temper support for importation legislation, which will likely be considered in the Democrat-led Congress (1"The Pink Sheet" Nov. 13, 2006, p. 3). In light of possible action and a recent U.S. law allowing personal importation, groups representing Canadian pharmacists, patients and distributors recently requested an immediate ban on bulk and retail drug exports. Health Canada says such a ban would be "premature" and that it sees no evidence to suggest individual importation poses an imminent threat to the Canadian drug supply...
You may also be interested in...
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.